Skip to content

Topical Morphine for Analgesia in Patients With Skin Grafts

Topical Morphine for Analgesia in Patients With Skin Grafts

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00362219
Enrollment
0
Registered
2006-08-09
Start date
2022-01-31
Completion date
2024-12-31
Last updated
2022-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Skin Transplantation

Keywords

topical, morphine, pain, skin-wound, skin-graft, peripheral analgesia, burn

Brief summary

The management of pain endured by patients after skin grafting is complex. Pain is the single most distressing symptom but as it is difficult to manage, it is often under-treated. These patients may experience pain from two types of wound: the original injury and from skin-donor sites, areas of healthy skin from which skin is surgically removed and used to cover the original injury. As the section of skin which is removed is standardized, the wound created at the donor site is uniform and so provides a model of an acute wound. Opioids (such as morphine) are the backbone of treating the moderate to severe pain experienced by any patient. But due to their potentially severe side effects and that some patients do not experience sufficient relief from the treatment, optimal treatment schedules are still being sought after. Topically applied morphine has provided effective and safe analgesia in several clinical models. We, therefore, wish to apply this treatment modality onto skin-graft donor wounds. If found to be effective this could be an appealing non-invasive method to treat the pain of this type of wound.

Detailed description

Administration of morphine into the knee joint is the best-studied clinical procedure documenting the use of topically-applied opioids. When 1-5 mg morphine were injected into the knee joint, patients experienced pain relief for up to 24 hours, whereas similar doses given systemically (i.e. intravenously) were effective for 2-4 hours. Furthermore, the analgesic effect was reversed when the opioid antagonist naloxone was injected into the knee joint. Both these findings indicate that the effect is mediated by local opioid receptors in the knee joint. Peripheral analgesic effects of opioids are not detectable in normal tissue but appear minutes to hours after initiation of inflammation. This suggests that opioid receptors are already present in the peripheral nerve terminals but under normal conditions they are not functional. Research on application of opioids to skin wounds is very sparse and has primarily been performed in palliative care patients. These reports demonstrate that topical opioid gel (morphine or diamorphine) provided rapid and effective relief. In some patients pain subsided within 20 minutes after application with a long-lasting (7-8 hours) effect. Fundamental aspects regarding topical application of opioids onto skin wounds are still lacking. For example, issues such as optimal dose and dose-effect relationships have not been investigated. We hope to determine these in this study.

Interventions

OTHERPlacebo

Gel with no active ingredient.

gel with 0.25 mg morphine per 100cm2 square of wound.

DRUGMorphine

Gel with 0.75 mg morphine per 100cm2 square of wound.

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing skin-grafting * American Society of Anesthesiologists (ASA) classification I-II * Written consent * Either sex * Able to self-asses and report their pain level

Exclusion criteria

* Alcohol abuse or addiction - current * Opioids and benzodiazepines abuse - life time * Known hypersensitivity to morphine * Major renal or hepatic dysfunction * Pregnancy or lactation * Sleep-apnoea-syndrome * Diabetes * Participation in other clinical studies

Design outcomes

Primary

MeasureTime frameDescription
Pain score in first 24 hours24 hours after application of the medicationSum of the differences in pain scores between the skin-donor site vs. original injury site taken over a 24 hour period after application of the medication.

Secondary

MeasureTime frameDescription
Time course of analgesia for each drug concentrationFirst 24 hours after surgeryTime course of analgesia for each drug concentration
Side effectsFirst 24 hours after surgeryPresence and severity of side effects: (a) central (nausea, vomiting, sedation, purities) and (b) local (burning, tingling, wheal, flare)
Supplementary analgesic medicationsFirst 24 hours after surgeryConcurrent, supplementary, rescue, analgesic medication (i.v.or oral morphine), given during the first 24 hours post operatively
Pain Score24 hours after surgeryPain score at skin-donor site using an abbreviated form of the McGill Pain Questionnaire
Pain score collectionTwice daily from day 2 post-op until day 8 post-opPain scores at donor and original injury, twice daily, from the second post-operative day until dressings are removed for the first time - up until 8th post-op day
Wound assessmentAverage day 12 post-operativeAssessment of the wound once the dressings are removed
Analgesic medicine from 2nd post-operative day until dressings are removed.Day 2 post-surgery through 12th post-op day on averageAnalgesic medication (type and dose), given from the second post-operative day until dressings are removed for the first time (= the 12th post-operataive day, on average).

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026